Veraxa Biotech AG Income Statement

Financials in millions CHF. Fiscal year is January - December.

Millions CHF. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023
Revenue	0.02	-	-
Revenue Growth	-	-	-
Cost of Revenue	0.01	-	-
Gross Profit	0.02	-	-
Selling, General & Admin	53.87	20.73	10.55
Research & Development	10.26	6.31	4.26
Operating Expenses	66.23	28.92	16.66
Operating Income	-66.22	-28.92	-16.66
Interest Expense	-0	-0	-0
Currency Exchange Gain (Loss)	-0.04	0.62	-1.05
Other Non Operating Income (Expenses)	0.05	0.01	0.05
EBT Excluding Unusual Items	-66.21	-28.28	-17.66
Other Unusual Items	-0.8	-0.47	-
Pretax Income	-67.01	-28.75	-17.66
Income Tax Expense	-0.39	-0.62	-1.11
Net Income	-66.61	-28.13	-16.54
Net Income to Common	-66.61	-28.13	-16.54
Net Income Growth	-	-	-
Shares Outstanding (Basic)	14	14	14
Shares Outstanding (Diluted)	14	14	14
Shares Change	3.01%	2.36%	-
EPS (Basic)	-4.60	-2.00	-1.21
EPS (Diluted)	-4.60	-2.00	-1.21
EPS Growth	-	-	-

Additional Metrics

Fiscal Year	FY 2025	FY 2024	FY 2023
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023
Free Cash Flow	-10.34	-7.84	-7.5
Free Cash Flow Per Share	-0.71	-0.56	-0.55
Gross Margin	66.00%	-	-
Operating Margin	-282662.75%	-	-
Profit Margin	-284359.22%	-	-
Free Cash Flow Margin	-44136.89%	-	-
EBITDA	-64.24	-27.05	-14.82
D&A For EBITDA	1.97	1.87	1.84
EBIT	-66.22	-28.92	-16.66

SEC Filings: 10-K · 10-Q